BACE1 influences clinical manifestations and central inflammation in relapsing remitting multiple sclerosis.
暂无分享,去创建一个
D. Centonze | F. Carbone | G. Matarese | G. Mandolesi | R. Furlan | E. Iezzi | A. Finardi | F. Buttari | A. Musella | F. De Vito | M. Stampanoni Bassi | Luana Gilio | L. Guadalupi | Giovanni Galifi | Antonio Bruno | Ettore Dolcetti | F. Azzolini | A. Borrelli
[1] N. Ginestet,et al. CSF β-amyloid is not a prognostic marker in multiple sclerosis patients. , 2022, Multiple sclerosis and related disorders.
[2] U. Dianzani,et al. Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis , 2022, Journal of Neurology.
[3] Yaohua Hu,et al. Reduction BACE1 expression via suppressing NF-κB mediated signaling by Tamibarotene in a mouse model of Alzheimer’s disease , 2021, IBRO neuroscience reports.
[4] B. Hosten,et al. STAT3 inhibition protects against neuroinflammation and BACE1 upregulation induced by systemic inflammation. , 2020, Immunology letters.
[5] A. Grimm,et al. Insights into Disease-Associated Tau Impact on Mitochondria , 2020, International journal of molecular sciences.
[6] K. Blennow,et al. CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease , 2020, Alzheimer's Research & Therapy.
[7] B. de Strooper,et al. The β-Secretase BACE1 in Alzheimer’s Disease , 2020, Biological Psychiatry.
[8] D. Galimberti,et al. Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. , 2019, Multiple sclerosis and related disorders.
[9] J. Hillert,et al. Disability worsening among persons with multiple sclerosis and depression , 2019, Neurology.
[10] Jian-mei Gao,et al. Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/IκB/NF-κB/BACE1 signaling pathway , 2019, Acta Pharmacologica Sinica.
[11] W. Hawse,et al. The Alzheimer’s Disease–Associated Protein BACE1 Modulates T Cell Activation and Th17 Function , 2019, The Journal of Immunology.
[12] Gerard Ill-Raga,et al. BACE1 Translation: At the Crossroads Between Alzheimer’s Disease Neurodegeneration and Memory Consolidation , 2019, Journal of Alzheimer's disease reports.
[13] J. Graves,et al. Mitochondrial Dysfunction and Multiple Sclerosis , 2019, Biology.
[14] S. Capellari,et al. Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias , 2018, Annals of clinical and translational neurology.
[15] J. DeLuca,et al. Recommendations for cognitive screening and management in multiple sclerosis care , 2018, Multiple sclerosis.
[16] M. Stecker,et al. Amyloid toxicity in Alzheimer’s disease , 2018, Reviews in the neurosciences.
[17] M. Bozzali,et al. CSF β-amyloid predicts prognosis in patients with multiple sclerosis , 2018, Multiple sclerosis.
[18] D. Centonze,et al. Amyloid-β Homeostasis Bridges Inflammation, Synaptic Plasticity Deficits and Cognitive Dysfunction in Multiple Sclerosis , 2017, Front. Mol. Neurosci..
[19] Nicholas C. Firth,et al. Progression of regional grey matter atrophy in multiple sclerosis , 2017, bioRxiv.
[20] M. Filippi,et al. Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis , 2017, Multiple sclerosis.
[21] L. Shaw,et al. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer’s Disease Markers in Elderly Healthy Participants , 2017, Journal of Alzheimer's disease : JAD.
[22] A. Kurne,et al. The association of cognitive impairment with gray matter atrophy and cortical lesion load in clinically isolated syndrome. , 2016, Multiple sclerosis and related disorders.
[23] D. Centonze,et al. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression , 2016, Journal of Neuroinflammation.
[24] J. Findlay,et al. BACE1 activity impairs neuronal glucose oxidation: rescue by beta-hydroxybutyrate and lipoic acid , 2015, Front. Cell. Neurosci..
[25] Y. Qian,et al. IL-17A is implicated in lipopolysaccharide-induced neuroinflammation and cognitive impairment in aged rats via microglial activation , 2015, Journal of Neuroinflammation.
[26] C Montomoli,et al. BREMSO: a simple score to predict early the natural course of multiple sclerosis , 2015, European journal of neurology.
[27] R. Vassar,et al. The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis , 2011, Journal of Neuroinflammation.
[28] D. Centonze,et al. Cognitive and Cortical Plasticity Deficits Correlate with Altered Amyloid-β CSF Levels in Multiple Sclerosis , 2011, Neuropsychopharmacology.
[29] K. Blennow,et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis , 2009, Multiple sclerosis.
[30] R. Vassar,et al. Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .
[31] Stefan J. Teipel,et al. Levels of β-Secretase (BACE1) in Cerebrospinal Fluid as a Predictor of Risk in Mild Cognitive Impairment , 2007 .
[32] B. de Strooper,et al. Regulated Intramembrane Proteolysis of the Interleukin-1 Receptor II by α-, β-, and γ-Secretase* , 2007, Journal of Biological Chemistry.
[33] P. Wong,et al. Bace1 modulates myelination in the central and peripheral nervous system , 2006, Nature Neuroscience.
[34] Deborah M. Miller,et al. The Goldman Consensus statement on depression in multiple sclerosis , 2005, Multiple sclerosis.
[35] N. Larocca,et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. , 1989, Archives of neurology.
[36] J. Sun,et al. BACE1-Deficient Mice Exhibit Alterations in Immune System Pathways , 2016, Molecular Neurobiology.
[37] H. Hampel,et al. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.